Anatomy & Physiology
Research Article
Volume 2 Issue 6 - 2016
The Efficacy of Niacin-Bound Chromium to Slow the Progression of Diabetic Nephropathy in Type II Diabetic Rats
Aaron Wood1,3, Taylor Claybaugh1,3, Yuriy Slyvka1,3, Jean Thuma2,3, Kelly McCall2,3*#, Sharon Inman1,3*#
1Department of Biomedical Sciences, Ohio University, Heritage College of Osteopathic Medicine, USA
2Department of Specialty Medicine, Ohio University, Heritage College of Osteopathic Medicine, USA
3The Diabetes Institute at Ohio University, USA
#Co-senior authorship
Received: June 30, 2016 | Published: August 02, 2016
*Corresponding author: Kelly McCall and Sharon Inman, Department of Biomedical Sciences, Ohio University, Department of Specialty Medicine, Ohio University, Heritage College of Osteopathic Medicine, The Diabetes Institute at Ohio University, USA, Email: ;
Citation: Wood A, Claybaugh T, Slyvka Y, Thuma J, McCall K, et al. (2016) The Efficacy of Niacin-Bound Chromium to Slow the Progression of Diabetic Nephropathy in Type II Diabetic Rats. MOJ Anat & Physiol 2(6): 00064. DOI: 10.15406/mojap.2016.02.00064


Animal and clinical studies suggest niacin-bound chromium (NBC) added to the diet improves glucose-insulin sensitivity, the ability to ameliorate inflammation, hypertension, and proteinuria. In addition to its lipid-lowering actions, NBC possesses potent antioxidant and anti-inflammatory properties. Rat studies demonstrated that T2DM decreases both the production and bioavailability of nitric oxide (NO), and we hypothesized that NBC supplementation will preserve NO production via increased endothelial nitric oxide synthase (eNOS) and decreased neuronal nitric oxide synthase (nNOS). NBC supplementation decreased levels of plasma creatinine in the treated diabetic rats compared to the untreated diabetic rats, and therefore preserved glomerular filtration rate (GFR). We provide evidence that this effect may also be due to increased levels of eNOS, which leads to renal microvascular vasodilation. Supplementation of NBC also lowered nNOS levels, which is a significant finding when considering the role of nNOS in T2DM. Marked improvements in fasting glucose and lower body weights were observed in the treated diabetic rats compared to the untreated diabetic rats. Therefore, these results demonstrate that NBC supplementation slows the progression of diabetic nephropathy (DN) in type 2 diabetic rats.

Keywords: Insulin Resistance; Diabetes Mellitus; Diabetic nephropathy; Hyperfiltration; Nitric oxide; Niacin-bound chromium; Efferent arterioles; Tubuloglomerular; Vasodilation; Lipid metabolism; Ameliorate hypertension


NBC: Niacin-Bound Chromium; NO: Nitric Oxide; GFR: Glomerular Filtration Rate; DN: Diabetic Nephropathy; CGMP: Cyclic Guanosine Monophosphate


Insulin resistance-related disorders such as type 2 diabetes mellitus (T2DM) and obesity have reached epidemic proportions in the recent years [1]. Diabetic nephropathy (DN) is the number one cause of end-stage renal failure [2]. The pathogenesis of DN perhaps occurs in two major stages: First, there is a vasodilation in the pre- and post-glomerular arterioles, which leads to higher intra-glomerular blood flow and pressure. This causes an early hyper filtration in the nephrons and eventually damages the glomerular membrane and allows for proteins, glucose and other molecules to be filtered by the glomerulus and then excreted in the urine. Secondly, the final irreversible stage is a vasoconstriction of the glomerular arterioles, which results in low blood flow and glomerular filtration rates (GFRs) [3]. The nitric oxide (NO) system has been shown to be altered in diabetes and in diabetic nephropathy [4]. NO is an important bioactive signaling molecule that mediates a variety of normal physiological functions, which, if altered, could contribute to the genesis of many pathological conditions, including diabetes [5]. We have previously reported alterations in the renal NO system in type 2 diabetic rats [6]. Niacin-bound chromium (NBC), at adequate dosing, increases insulin sensitivity, enhances NO activity, and appears to be non-toxic [7]. Endothelial nitric oxide synthase (eNOS) results in NO release from the endothelium of blood vessels and causes vasodilation via cyclic guanosine monophosphate (cGMP) [8]. Neuronal nitric oxide synthase (nNOS) is constitutively expressed in the kidney in the macula densa and endothelial cells of the efferent arterioles. It has also been demonstrated that NO derived from nNOS plays an important role in counteracting modulation of tubuloglomerular feedback (TGF)-mediated afferent arteriolar constriction [9,10]. Compared with normal rats, diabetic rats demonstrated enhanced renal hemodynamic responses to nNOS inhibition, suggesting increased basal activity of nNOS in the diabetic kidney [11]. Therefore, higher levels of renal eNOS compared to nNOS would be beneficial in the late stages of diabetic nephropathy to maintain renal blood flow via vasodilation.

In the later stages of diabetic nephropathy, the GFR decreases. This is due to significant renal vasoconstriction. The continued availability of NO would maintain GFR and renal blood flow. It has been presumed that in the kidney, eNOS predominates in the delivery of NO. Also, in recent studies, renal hemodynamics appears to be more sensitive to nNOS inhibition in diabetic rats [11]. In the present study, we hypothesized that NBC supplementation would increase NO bioavailability since it is upregulated by eNOS and by the inhibition of nNOS in the later stages of diabetic nephropathy. There is no clinically defined state of chromium deficiency, but diabetes has been shown to develop because of low chromium levels in experimental animals and in humans. These results suggest that there may be a more general relationship between chromium levels and glucose and/or lipid metabolism [12]. Niacin (nicotinic acid) is a water soluble vitamin of the B group. It is an essential nutrient required for the proper metabolism of carbohydrates, lipids and proteins [13]. In addition to the favorable effects on lipoproteins, several findings support the idea that niacin therapy may ameliorate inflammation. Niacin appears to attenuate the overexpression of NOS in a rat model of silica-induced lung inflammation [14]. NBC can ameliorate hypertension, dyslipidemias and diabetes mellitus, and may be useful in weight management [15]. Therefore, the hypothesis of this study was that a NBC diet would preserve renal function and slow the progression of diabetic nephropathy in a rat model of obesity-related T2DM. To test this hypothesis, we utilized the Zucker rat model of T2DM [16-22], and evaluated the effects of NBC supplementation on several components in T2DM: renal eNOS and nNOS, plasma creatinine, fasting blood glucose, and body weight. We report the novel findings that NBC supplementation preserved renal function, slowed the progression of diabetic nephropathy, and lowered nNOS levels in male Zucker rats, suggesting that NBC supplementation improves renal function by lowering nNOS levels.

Materials and Methods

Type 2 Diabetic rat model and groups

All animal work was conducted with approval from the Ohio University Institutional Animal Care and Use Committee. Our experiment included two genetically different groups of rats. One group was the obese Zucker rat (fa/fa). The second group was the lean Zucker rat (Fa/Fa). The obese Zucker rats are genetically leptin receptor deficient. This causes the animals to become hyperphagic, obese, and develop metabolic characteristics similar to that of T2DM [22]. The male obese Zucker rats (n = 16) and lean Zucker rats (n = 8) were obtained from Harlan Laboratories (Indianapolis, IN) at 4 weeks of age. Animals were housed in a climate-controlled vivarium with a 12:12 hour light-dark cycle and fed a standard laboratory diet libitum (Purina Mills, Brentwood MO) and water ad libitum for 4 days while the animals acclimate to laboratory conditions. After being acclimated to laboratory conditions for 4 days, they were randomly divided into three experimental groups (n = 8 rats/group). Group 1 served as the non-diabetic controls (Non-Diabetic Control, Lean) and was fed a standard ad libitum diet (Purina Mills, Brentwood, MO). Group 2 served as the type 2 diabetic controls (Diabetic Control, Placebo) and was fed a standard ad libitum diet (Purina Mills, Brentwood, MO. Group 3 (Diabetic Treatment, NBC) was fed a niacin bound chromium (NBC) enriched food pellet ad libitum (Purina Mills, Brentwood, MO). The amount of niacin-bound chromium supplement the rat consumes is approximately 1.2-1.9 mg per kg body weight. Each group was maintained on their respective diet for a total of 12 weeks.

Testing protocol

After the initial 4 day acclimation period, rat body weights were recorded and then taken every two weeks. At the initiation of the diet, blood samples were obtained. This was repeated at weeks 2, 6, and 12. Fasting blood glucose measurements were taken using the Accu-Check (Roche Diagnostics) blood glucose monitoring system. Relative renal function (plasma creatinine) was determined by using a plasma creatinine assay kit (Cayman Chemicals, Ann Arbor, MI).

Post-Euthanasia analysis

At the end of the 12 week period, rats were euthanized and one kidney was removed then the renal medulla and renal cortex were separated, collected and stored in liquid nitrogen for renal eNOS and nNOS protein level analyses by Western blot.

Western blot Analyses of eNOS and nNOS

Western blots were performed to assess the kidney cortex and medulla protein levels of eNOS and nNOS isoforms. Frozen kidney samples were homogenized in HEPES/sucrose buffer containing proteinase inhibitors and centrifuged at 8000g for 20 min at 4°C. Electrophoresis was performed with unboiled samples at 4°C on 5-15% Tris-HCl SDS-PAGE gradient gels. Total protein concentration was determined for each sampled supernatant using a Bicinchoninic.


Weight Gain

The three groups of rats gained weight at different rates. There were no significant differences in weight gain among the rats. The NBC treatment group, overall, had lower body weights than the Diabetic control group, for weeks 4-12. The Lean control group had the lowest body weight for all time points (Figure 1).

Figure 1: Effect of Niacin-bound chromium supplementation on weight gain over 12 weeks. Data are represented as means ± standard deviations.

Fasting Blood Glucose

Glucose levels in the NBC treatment group were significantly higher at weeks 0 and 12 than those in the Non-Diabetic Control rats and significantly lower than in the Diabetic Control rats at weeks 2 and 6. Fasting blood glucose levels in the Diabetic Control rats were higher at all weeks than those in the Non-Diabetic Control rats. NBC supplementation did improve fasting blood glucose levels after initiation of diet, but did not improve fasting blood glucose levels at the termination of the experiment (i.e., 12 weeks) (Figure 2).

Figure 2: Effect of Niacin-bound chromium on fasting glucose levels over 12 weeks. Non-Diabetic Control versus Diabetic Control: *P< 0.05; Non-Diabetic Control versus NBC: $P < 0.05; Diabetic Control versus NBC: #P < 0.05.

Plasma Creatinine

Plasma creatinine levels in NBC rats were significantly lower at week 6 and week 12 than those in the Non-Diabetic Control rats and in the Diabetic Control rats (Figure 3). Plasma creatinine levels in the Diabetic Control rats were higher at all weeks than those in the Non-Diabetic Control rats. NBC supplementation did improve plasma creatinine levels after initiation of diet and throughout the 12 weeks of feeding (Figure 3).

Figure 3: Effect of Niacin-bound chromium supplementation on plasma creatinine levels over 12 weeks. Data are represented as means ± standard deviations. Non-Diabetic Control versus NBC: $ p < 0.05; Diabetic Control versus NBC: # p < 0.05.

eNOS and nNOS Protein Levels

In our experiment we was observed 74, 77, and 130 kDa eNOS splice forms. The induction of diabetes was associated with a significant decrease of the 74 and 130 kDa isoforms and total amount of eNOS in the kidney cortex and the74 kDa eNOS splice form in the rentel kidney medulla. NBC treatment in cortex resulted in positive but non-significant changes of previously decreased eNOS expression and appearance of additional 77 kDa splice form. The same time it was observed normalization of 74 kDa eNOS splice form in medulla (Table 1). .

Non-Diabetic Control

Diabetic Control

Diabetic +NBC


74 kDa





Not detected

Not detected


130 kDa









74 kDa




130 kDa








Table 1: Effect of Niacin-bound chromium supplementation on eNOS/β-actin ratio in the kidney cortex and medulla (*p<0.05 vs. control).

In the case of nNOS, We observed the presence of the 73, 136, and 152 kDa splice forms. Diabetic Control animals displayed a significant decrease of the 73 and 136 kDa and total amount of nNOS in the rentel cortex . Where as the 152 kDa isoform was not detected. In Diabetic Control animals there was only a decrease 73 kDa nNOS isoform. NBC treatment induced a further decrease of all detected nNOS splice forms (Table 2).


Non-Diabetic Control

Diabetic Control

Diabetic +NBC


73 kDa




136 kDa




152 kDa


Not detected

Not detected






73 kDa




136 kDa








Table 2: Effect of Niacin-bound chromium supplementation on nNOS/β-actin ratio in the kidney cortex and medulla (*p<0.05 vs. control, #p<0.05 vs. high sucrose diet).


Dietary NBC supplementation given to type 2 diabetic rats preserved renal function compared to type 2 diabetic rats’ not receiving NBC supplementation. When NBC was supplemented to the diet of type 2 diabetic rats, it enhanced the activity of NO via NOS. NO is a highly reactive free radical species, generated by the enzyme, NOS [5]. It is believed that the NO produced, is then activated via eNOS into guanylyl cyclase (GC). GC is then transformed into cyclic guanosine monophosphate (cGMP) via the biosynthetic pathway [17] owing to the rise of NO and eNOS, there were increased levels of the second messenger cGMP. The increased cGMP acts on the vascular endothelium, resulting in vasodilation, which then raises the GFR. Another interesting observation is the association with the NOSs, nNOS and eNOS. Increased vasodilation of efferent arterioles and decreased vasodilation of afferent arterioles leads to increased GFR. Greater vasodilation slows the progression of renal failure and diabetic nephropathy by maintaining renal blood flow [18].

It is speculated that renal vasodilation most likely occurred in this study due to the observed greater levels of mediators involved in the NO biosynthetic pathway. Estimation of GFR based on plasma creatinine is a practical, clinically relevant approach to assessing kidney function in people with T2DM. Plasma creatinine levels are typically higher in type 2 diabetic patients than non-diabetic patients [19]. Low plasma creatinine levels indicated increased filtration for those diabetic rats supplemented with NBC. The NBC-treated diabetic rats had lower plasma creatinine levels throughout the entire experimental period when compared to both non-diabetic and diabetic control rats. Therefore, low plasma creatinine levels showed increased filtration, and presumably increased GFR, for those diabetic rats supplemented with NBC. Once the T2DM diagnosis is made, a dietary NBC supplementation used as an early intervention may prove to be beneficial in these patients.

Increased levels of eNOS and lower levels of nNOS in the renal medulla and cortex were detected in the NBC-supplemented rats compared to the diabetic control rats. eNOS causes positive activation of NO leading to cGMP and vasodilation [20]. nNOS-derived nitric oxide plays a role in the control of systemic and renal hemodynamics in normal and diabetic rats. Diabetic rats have shown increased activity of this pathway in the diabetic kidney [11]. It is important to note that in the normal, non-diabetic kidney, nNOS is prevalent but does not have much of a biological role. In a diabetic kidney, nNOS leads to increased vasoconstriction. Therefore, it is to be expected to observe low levels of nNOS in the NBC-treated rats when compared to both non-diabetic control and diabetic control rats, as can be seen in this experiment.

NBC can ameliorate hypertension, dyslipidemias and diabetes mellitus, and may be useful in weight management. There is evidence to suggest that chromium supplementation may improve insulin sensitivity and glucose metabolism in patients with glucose intolerance [12]. Numerous non-drug substances, such as trivalent chromium, have been shown to influence the glucose-insulin system in a favorable manner. Importantly, most natural substances that affect the glucose-insulin system work satisfactorily over long periods of time and are safe enough to be used chronically. Natural alternatives could prove useful to ameliorate or even prevent the development of insulin resistance [21]. In our experiment we observed a beneficial effect on the preservation of glomerular filtration rate, via lowered plasma creatinine levels, increased eNOS, and inhibition of nNOS, in our diabetic model throughout the study.

Fasting blood glucose levels were significantly lower in the NBC-treated rats compared to the Diabetic Control rats at weeks 2 and 6. At week 12, the NBC-treated rats had similar fasting blood glucose levels when compared to the Diabetic Controls. The Diabetic Control rats had significantly higher fasting blood glucose levels at all experimental times when compared to Non-Diabetic Control rats. In one study, no effect of NBC supplementation was observed on fasting blood glucose levels [22]. An oral glucose tolerance test (OGTT) revealed a significantly improved clearance of blood glucose between 1 and 2 h of glucose challenge in NBC-supplemented mice [22]. Therefore, an OGTT should be performed to confirm the implications shown from fasting blood glucose. Body weight measurements resulted in the Diabetic control and NBC-treated groups gaining weight when compared to control rats. Although the NBC treated rats weighed less at all experimental times, they only weighed significantly less at weeks 8 and 12 when compared to diabetic rats, suggesting there is a correlation between duration of treatment and administered NBC.

Together, these findings imply that NBC supplementation has beneficial effects in preserving renal function in type 2 diabetic subjects when implemented at the initial time of diagnosis. In future studies, alterations in the NO pathway need to be determined. To further support this study’s findings, creatinine clearance (urine and plasma creatinine levels, urine output, and time), plasma cGMP, and OGTT should be tested. Also, the different stages of diabetes and an extended experimental timeline should be considered. Early biopsy of the kidney might be an indicator of the severity of the progression of diabetic nephropathy, before renal failure, and therefore provide further insight into the timing of early treatment to slow its progression. The inexpensive dietary NBC supplementation could be considered a nutritional supplement administered to type 2 diabetic patients, as an alternative to other available anti-diabetic drugs.


Niacin-bound chromium may be an inexpensive alternative for type 2 diabetics. In this study, early intervention with Niacin-bound chromium supplementation was beneficial by preserving renal function, presumably via increased eNOS levels leading to renal vasodilation. Also, renal function and hemodynamics have been shown to be enhanced when nNOS is inhibited, as was observed in this study since significantly decreased levels of nNOS was found in the NBC-supplemented rats. Marked improvements were also seen in body weight and fasting glucose with supplementation of NBC. Additional studies are needed to examine the many mediators involved in the nitric oxide pathway, renal function throughout the experimental time frame, and the effects NBC has on insulin resistance to further support this claim.


The authors would like to acknowledge that this study was funded by the Ohio University Heritage College of Osteopathic Medicine Centers for Osteopathic Research and Education.


  1. Remuzzi, Macia, Ruggenenti P (2006) Prevention and Treatment of Diabetic Renal Disease in Type 2 Diabetes: The BENEDICT Study. J Am Soc Nephrol 17(4 Suppl 2); S90-S97.
  2. Hostetter TH, Troy JL, Brenner BM (1981) Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19(3); 410-415.
  3. Fowler M (2008) Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes 26(2); 77-82.
  4. Ragoobirsingh D, McGrowder D, Dasgupta T, Brown P (2004) The effect of nitric oxide on glucose metabolism. Mol Cell Biochem 263(1-2); 29-34.
  5. Claybaugh, Decker, Kelly Mc Call, Yuriy Slyvka, Jerrod Steimle, et al. (2014) L-arginine supplementation in type II diabetic rats preserves renal function and improves insulin sensitivity by altering the nitric oxide pathway. International Journal of Endocrinology p. 7.
  6. Perricone NV, Bagchi D, Echard B, Preuss HG (2010) Long-term metabolic effects of different doses of niacin-bound chromium on Sprague-Dawley rats. Mol Cell Biochem 338(1-2); 91-103.
  7. Bourgoin F, Bachelard H, Badeau M, Mélançon S, Pitre M, et al. (2008) Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet. Am J Physiol Heart Circ Physiol 295 (3); H1044-H1055.
  8. Cervenka L, Kramer HJ, Maly J, Heller J (2001) Role of nNOS in Regulation of Renal Function in Angiotensin II-Induced Hypertension. Hypertension 38(2); 280-285.
  9. Yabuki A, Tahara T, Taniguchi K, Matsumoto M, Suzuki S (2006) Neuronal Nitric Oxide Synthase and Cyclooxygenase-2 in Diabetic Nephropathy of Type 2 Diabetic OLETF Rats. Exp Anim 55(1); 17-25.
  10. Komers R, Oyama TT, Chapman JG, Allison KM, Anderson S (2000) Effects of Systemic Inhibition of Neuronal Nitric Oxide Synthase in Diabetic Rats. Hypertension 35(2); 655-661.
  11. Cefalu WT, Hu FB (2004) Role of Chromium in Human Health and in Diabetes. Diabetes Care 27(11); 2741-2751.
  12. Döger M, Sokmen BB, Yanardag R (2011) Combined effects of niacin and chromium treatment on heart of hyperlipidemic rats. Human and Experimental Toxicology 30(10); 1561-1566.
  13. Yu B, Zhao S (2007) Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects. Medical Hypotheses 69; 90-94.
  14. Talpur N, Echard BW, Yasmin T, Bagchi D, Preuss HG (2003) Effects of niacin-bound chromium, Maitake mushroom fraction SX and (-)-hydroxycitric acid on the metabolic syndrome in aged diabetic Zucker fatty rats. Mol Cell Biochem 252(1-2); 369-377.
  15. Dutta, Podolin, Davidson MB, Davidoff AJ (2001) Cardiomyocyte Disfunction in Sucrose-Fed Rats is Associated with Insulin Resistance. Diabetes 50(5); 1186-1192.
  16. Aiello S, Remuzzi G, Noris M (1998) Nitric oxide/endothelin balance after nephron reduction. Kidney Int Suppl 65; S63-S67.
  17. Toba H, Sawai N, Morishita M, Murata S, Yoshida M (2009) Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 612(1-3); 106-114.
  18. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, et al. (2010) Assessment of kidney function in type 2 diabetes. Nephrology (carlton)15(suppl1); S146-S161.
  19. Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, et al. (2013) Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91phox to the protective effect of 5, 14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock. Nitric Oxide 33; 18-41.
  20. Preuss H G , Echard B, Bagchi D, Perricone NV, Zhuang C (2007) Enhanced insulin-hypoglycemic activity in rats consuming a specific glycoprotein extracted from maitake mushroom. Mol Cell Biochem 306(1-2); 105-113.
  21. Rink C, Roy S, Khanna S, Rink T, Bagchi D, Sen CK (2007) Transcriptome of the subcutaneous adipose tissue in response to oral supplementation of type 2 Leprdb obese diabetic mice with niacin-bound chromium. Physiol Genomics 27(3); 370-379.
  22. Wang B, Chandrasekera PC, Pippin JJ (2014) Leptin and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes. Curr Diabetes Rev 10(2); 131-145
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy